Investing.com -- Citius Oncology, Inc. (NASDAQ:CTOR)股价上涨4.1%,此前该公司宣布与Cencora达成分销服务协议,用于其获FDA批准的免疫疗法LYMPHIR。 与前身为AmerisourceBergen的Cencora达成的协议将扩大LYMPHIR(denileukin diftitox-cxdl)的分销网络。该药物于2024年8月获FDA...
Source LinkInvesting.com -- Citius Oncology, Inc. (NASDAQ:CTOR)股价上涨4.1%,此前该公司宣布与Cencora达成分销服务协议,用于其获FDA批准的免疫疗法LYMPHIR。 与前身为AmerisourceBergen的Cencora达成的协议将扩大LYMPHIR(denileukin diftitox-cxdl)的分销网络。该药物于2024年8月获FDA...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.